Table 2.

Summary of systematic reviews on hepatitis C virus treatment in patients with renal disease

HCV and renal condition/ref. and year	No. of trials/patients	Types and duration of treatment	SVR	Notes
Glomerulonephritis
Fabrizi et al[90] (2013)	Trials = 10	Combination of PegIFN plus ribavirin	52%	Dropout rate = 15%
		6 mo to more than 12 mo
	Patients = 300	Conventional IFN plus ribavirin	32%
		6 mo to more than 12 mo
Acute Hepatitis C
Fabrizi et al[116] (2012)	Trials = 8	Conventional or PegIFN	58%	Dropout rate = 9%
	Patients = 173	3 mo to 12 mo		Genotype 1 = 49%
Hemodialysis
Fabrizi et al[117] (2008)	Trials = 28	Conventional IFN or PegIFN	31%-39%	Dropout rate = 19%-27%
	Patients = 645
Fabrizi et al[118] (2010)	Trials = 16	PegIFN	33%-38%	Dropout rate = 23%
	Patients = 254	24-48 wk
Fabrizi et al[122] (2011)	Trials = 10	Conventional interferon + ribavirin or Peg-IFN + ribavirin	56%	Dropout rate = 25%
	Patients = 151	24-48 wk		Genotype 1 = 58.3%
Renal transplant
Wei et al[128] (2014)	Trials = 12	Conventional IFN monotherapy or Conventional IFN plus ribavirin or PegIFN + ribavirin	26.6% PegIFN base = 40.6%	Dropout rate = 21.1%
	Patients = 140	3.5 to 33 mo	Conventional IFN base = 20.9%	Graft rejection rates = 4%

HCV: Hepatitis C virus; SVR: Sustained viral response; IFN: Interferon; PegIFN: Pegylated interferon.